DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information

The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any indepe...

Full description

Saved in:
Bibliographic Details
Published in:Cell death & disease 2014-02, Vol.5 (2), p.e1051-e1051
Main Authors: Amelio, I, Gostev, M, Knight, R A, Willis, A E, Melino, G, Antonov, A V
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Clinical Trials as Topic
Computational Biology - instrumentation
Databases, Factual
Drug Approval
Drug Evaluation
Drug Repositioning - instrumentation
Humans
Internet
Neoplasms - drug therapy
Neoplasms - mortality
Original
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of existing drugs for new therapeutic applications, commonly referred to as drug repositioning, is a way for fast and cost-efficient drug discovery. Drug repositioning in oncology is commonly initiated by in vitro experimental evidence that a drug exhibits anticancer cytotoxicity. Any independent verification that the observed effects in vitro may be valid in a clinical setting, and that the drug could potentially affect patient survival in vivo is of paramount importance. Despite considerable recent efforts in computational drug repositioning, none of the studies have considered patient survival information in modelling the potential of existing/new drugs in the management of cancer. Therefore, we have developed DRUGSURV; this is the first computational tool to estimate the potential effects of a drug using patient survival information derived from clinical cancer expression data sets. DRUGSURV provides statistical evidence that a drug can affect survival outcome in particular clinical conditions to justify further investigation of the drug anticancer potential and to guide clinical trial design. DRUGSURV covers both approved drugs (∼1700) as well as experimental drugs (∼5000) and is freely available at http://www.bioprofiling.de/drugsurv.
ISSN:2041-4889
2041-4889
DOI:10.1038/cddis.2014.9